{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:55:59Z","timestamp":1790693759862,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2504100"],"award-info":[{"award-number":["2022YFC2504100"]}]},{"name":"National Key Research and Development Program of China","award":["82371124"],"award-info":[{"award-number":["82371124"]}]},{"name":"National Natural Science Foundation of China","award":["2022YFC2504100"],"award-info":[{"award-number":["2022YFC2504100"]}]},{"name":"National Natural Science Foundation of China","award":["82371124"],"award-info":[{"award-number":["82371124"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Allergic rhinitis (AR) is a common and increasingly prevalent chronic inflammatory disorder of the nasal mucosa that severely impacts patients\u2019 quality of life, causing symptoms like nasal congestion, sneezing, and itching. AR is primarily mediated by immunoglobulin E (IgE) when allergens are present, making it challenging to manage despite available therapies like pharmacotherapy, immunotherapy, and surgery. Recently, research has focused on biologics as an emerging therapeutic option for AR. Biologics target specific immune pathways in type 2 inflammation, which underlies many allergic diseases including AR. Biologics offer a targeted and potentially more effective alternative to traditional therapies, addressing the underlying immune mechanisms rather than simply alleviating symptoms. Based on key clinical trial evidence, this paper tentatively proposes a multidimensional strategy for selecting biologics in AR, integrating serum IgE levels, disease phenotypes (seasonal\/persistent), and comorbid characteristics to guide individualized treatment. However, the long-term cost-effectiveness, optimal dosing regimens, and patient adherence to biologics require further validation through real-world data. Despite these challenges, recent advancements in biologics represent a promising step forward in AR management. With ongoing research and clinical trials, biologics may soon provide more effective and lasting relief for patients suffering from allergic rhinitis.<\/jats:p>","DOI":"10.3390\/ijms26104509","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T04:13:44Z","timestamp":1746764024000},"page":"4509","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recent Studies and Prospects of Biologics in Allergic Rhinitis Treatment"],"prefix":"10.3390","volume":"26","author":[{"given":"Xiangning","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhe","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianxue","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyue","family":"Huo","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyue","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: Allergic rhinitis-2023","volume":"13","author":"Wise","year":"2023","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1398-9995.2007.01620.x","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1398-9995.2007.01549.x","article-title":"A survey of the burden of allergic rhinitis in Europe","volume":"62","author":"Canonica","year":"2007","journal-title":"Allergy"},{"key":"ref_6","unstructured":"Subspecialty Group of Rhinology, Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery, and Subspecialty Group of Rhinology, Society of Otorhinolaryngology Head and Neck Surgery, Chinese Medical Association (2022). Chinese guideline for diagnosis and treatment of allergic rhinitis (2022, revision). Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chin. J. Otorhinolaryngol. Head Neck Surg., 57, 106\u2013129."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e12094","DOI":"10.1002\/clt2.12094","article-title":"Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin. Transl. Allergy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jaci.2020.07.007","article-title":"Rhinitis 2020: A practice parameter update","volume":"146","author":"Dykewicz","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaci.2009.05.013","article-title":"Burden of allergic rhinitis: Results from the Pediatric Allergies in America survey","volume":"124","author":"Meltzer","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.2500\/aap.2012.33.3603","article-title":"Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific adult surveys","volume":"33","author":"Meltzer","year":"2012","journal-title":"Allergy Asthma Proc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.otohns.2008.05.019","article-title":"Rhinitis symptoms and comorbidities in the United States: Burden of rhinitis in America survey","volume":"139","author":"Derebery","year":"2008","journal-title":"Otolaryng. Head Neck Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2024.0530","article-title":"Allergic Rhinitis: A Review","volume":"331","author":"Bernstein","year":"2024","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/cea.13333","article-title":"Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study","volume":"49","author":"Menditto","year":"2019","journal-title":"Clin. Exp. Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/all.14561","article-title":"Clinical characteristics of allergic rhinitis patients in 13 metropolitan cities of China","volume":"76","author":"Zheng","year":"2021","journal-title":"Allergy"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1365-2222.1998.00237.x","article-title":"Symptom control in patients with hay fever in UK general practice: How well are we doing and is there a need for allergen immunotherapy?","volume":"28","author":"White","year":"1998","journal-title":"Clin. Exp. Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12245","DOI":"10.1002\/clt2.12245","article-title":"Persistence in allergen immunotherapy: A longitudinal, prescription data-based real-world analysis","volume":"13","author":"Pfaar","year":"2023","journal-title":"Clin. Transl. Allergy"},{"key":"ref_17","first-page":"e71408","article-title":"Efficacy of Biologic Therapies in the Management of Allergic Rhinitis: A Systematic Review","volume":"16","author":"Yamani","year":"2024","journal-title":"Cureus J. Med. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1126\/science.1221064","article-title":"New paradigms in type 2 immunity","volume":"337","author":"Pulendran","year":"2012","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41423-025-01261-2","article-title":"Type 2 immunity in allergic diseases","volume":"22","author":"Ogulur","year":"2025","journal-title":"Cell Mol. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"00576","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1111\/all.15454","article-title":"Update on pathomechanisms and treatments in allergic rhinitis","volume":"77","author":"Zhang","year":"2022","journal-title":"Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/alr.22206","article-title":"Sentinels at the wall: Epithelial-derived cytokines serve as triggers of upper airway type 2 inflammation","volume":"9","author":"Patel","year":"2019","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11882-015-0581-6","article-title":"Insights into Group 2 Innate Lymphoid Cells in Human Airway Disease","volume":"16","author":"Karta","year":"2016","journal-title":"Curr. Allergy Asthma Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jaci.2020.04.010","article-title":"Epithelial barriers in allergy and asthma","volume":"145","author":"Hellings","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","first-page":"e68607","article-title":"Recent Advances in Allergic Rhinitis: A Narrative Review","volume":"16","author":"Tidke","year":"2024","journal-title":"Cureus J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev-immunol-051116-052350","article-title":"Th2 Cells in Health and Disease","volume":"35","author":"Nakayama","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2016.06.033","article-title":"Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases","volume":"138","author":"Akdis","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_30","first-page":"52","article-title":"Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia","volume":"40","author":"Wu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaci.2013.12.1086","article-title":"Allergen challenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate lymphoid cells that express CD84","volume":"133","author":"Doherty","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1111\/all.14526","article-title":"Role of IL-25, IL-33, and TSLP in triggering united airway diseases toward type 2 inflammation","volume":"75","author":"Hong","year":"2020","journal-title":"Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ghezzi, M., Pozzi, E., Abbattista, L., Lonoce, L., Zuccotti, G.V., and D\u2019Auria, E. (2021). Barrier Impairment and Type 2 Inflammation in Allergic Diseases: The Pediatric Perspective. Children, 8.","DOI":"10.3390\/children8121165"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Palomares, \u00d3., S\u00e1nchez-Ram\u00f3n, S., D\u00e1vila, I., Prieto, L., de Llano, L.P., Domingo, C., and Nieto, A. (2017). dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061328"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"102076","DOI":"10.1016\/j.eclinm.2023.102076","article-title":"Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): A multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"61","author":"Zhang","year":"2023","journal-title":"Eclinicalmedicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jaci.2013.11.027","article-title":"Mechanisms underlying the neuronal-based symptoms of allergy","volume":"133","author":"Undem","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.201609-1846OC","article-title":"Mucosal Type 2 Innate Lymphoid Cells Are a Key Component of the Allergic Response to Aeroallergens","volume":"195","author":"Dhariwal","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis","volume":"376","author":"Mennini","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients with Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_41","unstructured":"(2025, April 26). Drug Clinical Trial Registration and Information Disclosure Platform. Available online: http:\/\/www.chinadrugtrials.org.cn\/index.html."},{"key":"ref_42","unstructured":"(2025, April 26). International Clinical Trials Registry Platform (ICTRP). Available online: https:\/\/www.who.int\/clinical-trials-registry-platform."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/JAA.S288952","article-title":"Effectiveness and Response Predictors of Omalizumab in Treating Patients with Seasonal Allergic Rhinitis: A Real-World Study","volume":"14","author":"Ma","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.imlet.2020.08.002","article-title":"Long-term omalizumab efficacy in allergic rhinitis","volume":"227","author":"Cavaliere","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/1945892419884774","article-title":"Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials","volume":"34","author":"Yu","year":"2020","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2332\/allergolint.55.379","article-title":"Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis","volume":"55","author":"Okubo","year":"2006","journal-title":"Allergol. Int."},{"key":"ref_47","unstructured":"(2025, April 26). Database of Approved and Licensed Drugs in Japan. Available online: https:\/\/www.drugfuture.com\/pmda\/."},{"key":"ref_48","unstructured":"(2025, April 26). Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024. Available online: http:\/\/www.longbio.com\/news1\/22.html."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaci.2017.11.051","article-title":"Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma","volume":"142","author":"Weinstein","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/all.16001","article-title":"Differential modulation of allergic rhinitis nasal transcriptome by dupilumab and allergy immunotherapy","volume":"79","author":"Wipperman","year":"2024","journal-title":"Allergy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/JAA.S318892","article-title":"Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial","volume":"14","author":"Corren","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CM9.0000000000002747","article-title":"Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial","volume":"137","author":"Zhao","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2024.07.1447","article-title":"Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"91","author":"Zhao","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, J., Wang, M., Li, X., Yan, B., Liu, J., Shi, L., Cao, Z., Feng, Y., and Liu, W. (2025). Stapokibart for moderate-to-severe seasonal allergic rhinitis: A randomized phase 3 trial. Nat. Med.","DOI":"10.1038\/s41591-025-03651-5"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"102467","DOI":"10.1016\/j.eclinm.2024.102467","article-title":"Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): An investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial","volume":"69","author":"Zhang","year":"2024","journal-title":"Eclinicalmedicine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12931-021-01746-4","article-title":"Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions","volume":"22","author":"Gibson","year":"2021","journal-title":"Respir. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000023924","article-title":"Effects of anti-IL-5 monoclonal antibody on the murine model of nasal allergy","volume":"116","author":"Asakura","year":"1998","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.4049\/jimmunol.168.6.3017","article-title":"Pathogenesis of murine experimental allergic rhinitis: A study of local and systemic consequences of IL-5 deficiency","volume":"168","author":"Saito","year":"2002","journal-title":"J. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial","volume":"151","author":"Corren","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"155891","DOI":"10.1016\/j.cyto.2022.155891","article-title":"Interleukin-33 (IL-33): A critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine","volume":"156","author":"Cayrol","year":"2022","journal-title":"Cytokine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1398-9995.2011.02735.x","article-title":"Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis","volume":"67","author":"Kim","year":"2012","journal-title":"Allergy"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"AB73","DOI":"10.1016\/j.jaci.2016.12.286","article-title":"A Phase 1 Study of ANB020, an anti-IL-33 monoclonal Antibody in Healthy Volunteers","volume":"139","author":"Londei","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e131347","DOI":"10.1172\/jci.insight.131347","article-title":"Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy","volume":"4","author":"Chinthrajah","year":"2019","journal-title":"JCI Insight"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5114\/ceji.2014.47724","article-title":"Additive anti-allergic effects of anti-interleukin-33 and anti-Siglec-F treatments in a murine model of allergic asthma","volume":"39","author":"Jang","year":"2014","journal-title":"Cent. Eur. J. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1081-1206(10)62171-0","article-title":"Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis","volume":"91","author":"Chervinsky","year":"2003","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1398-9995.2004.00550.x","article-title":"Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR","volume":"59","author":"Vignola","year":"2004","journal-title":"Allergy"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.anai.2020.05.026","article-title":"Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis","volume":"125","author":"Busse","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jaip.2014.02.001","article-title":"Omalizumab for the treatment of inadequately controlled allergic rhinitis: A systematic review and meta-analysis of randomized clinical trials","volume":"2","author":"Tsabouri","year":"2014","journal-title":"J. Allergy Clin. Immunol.-Pract."},{"key":"ref_70","first-page":"501","article-title":"Omalizumab for the treatment of allergic rhinitis: A systematic review and meta-analysis","volume":"59","author":"Tsabouri","year":"2021","journal-title":"Rhinology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/alr.23268","article-title":"Combination of omalizumab with allergen immunotherapy versus immunotherapy alone for allergic diseases: A meta-analysis of randomized controlled trials","volume":"14","author":"Zhang","year":"2024","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2222.2008.03121.x","article-title":"Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma","volume":"39","author":"Kopp","year":"2009","journal-title":"Clin. Exp. Allergy"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.waojou.2022.100737","article-title":"Risks and safety of biologics: A practical guide for allergists","volume":"16","author":"Sitek","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaci.2007.09.032","article-title":"American Academy of Allergy, Asthma & Immunology\/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis","volume":"120","author":"Cox","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_77","first-page":"5448","article-title":"Safety profile of Dupilumab during pregnancy: A data mining and disproportionality analysis of over 37,000 reports from the WHO individual case safety reporting database (VigiBase)","volume":"25","author":"Damiani","year":"2021","journal-title":"Eur. Rev. Med. Pharm."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/13543784.2019.1571581","article-title":"New drugs in early-stage clinical trials for allergic rhinitis","volume":"28","author":"Heffler","year":"2019","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4509\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:29:47Z","timestamp":1760030987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/10\/4509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":79,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ijms26104509"],"URL":"https:\/\/doi.org\/10.3390\/ijms26104509","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]}}}